• Pei Yang, Chuanbao Zhang, Jinquan Cai, Gan You, Yinyan Wang, Xiaoguang Qiu, Shouwei Li, Chenxing Wu, Kun Yao, Wenbin Li, Xiaoxia Peng, Wei Zhang, and Tao Jiang.
• Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
• Oncotarget. 2016 Nov 29; 7 (48): 80091-80100.

PurposeAge is a major prognostic factor for malignant gliomas. However, few studies have investigated the management of gliomas in young adults. We determined the role of survival and treatment in young adults with advanced gliomas in a large population from the Chinese Glioma Genome Atlas (CGGA).MethodsThis study included 726 adults (age ≥ 18) with histologically proven anaplastic glioma or glioblastoma multiforme (GBM). The overall and progression-free survival was determined in young (age < 50) and older groups (age ≥ 50).ResultsThe study included an older group (OP) of 264 patients and a younger group (YP) of 462patients. In the OP group with GBM and anaplastic glioma, patients treated with RT combined with temozolomide (TMZ) manifested significantly longer OS and PFS compared with patients assigned to RT alone (P < 0.05). In contrast, the YP group diagnosed with anaplastic glioma failed to show any survival advantage with RT plus TMZ compared with RT alone.ConclusionsWe observed no survival benefit in young adults (age < 50) with anaplastic glioma when treated with TMZ combined with RT. Our findings warrant further investigation of younger patients diagnosed with anaplastic glioma treated with radiotherapy plus TMZ chemotherapy.

42 keywords...

hide…